Shi, W <br/><br/>
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  01 2017 
 - 128-135 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw434  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biopsy, Fine-Needle--methods<br/>Breast Neoplasms--drug therapy<br/>Class I Phosphatidylinositol 3-Kinases--genetics<br/>DNA, Neoplasm--genetics<br/>Female<br/>Humans<br/>Lapatinib<br/>Molecular Targeted Therapy<br/>Mutation<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Trastuzumab--administration & dosage<br/>Exome Sequencing<br/>rhoA GTP-Binding Protein--genetics